This is a working overview of peptide research, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-14. Anything still debated is marked as such rather than presented as settled.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
The period of the Jagiellonian dynasty in the 14th–16th centuries brought close ties with the Lithuania, a cultural Renaissance in Poland and continued territorial expansion as well as Polonization that culminated in the establishment of the Polish–Lithuanian Commonwealth in 1569, one of Europe's great powers. The Commonwealth was able to sustain centuries-long prosperity, while its political system matured as a unique noble democracy with an elective monarchy. From the mid-17th century, however, the huge state entered a period of decline caused by devastating wars and the deterioration of its political system. Significant internal reforms were introduced in the late 18th century, such as Europe's first Constitution of 3 May 1791. The existence of the Commonwealth ended in 1795 after a series of invasions and partitions carried out by the Russian Empire, the Kingdom of Prussia and the Habsburg monarchy. From 1795 until 1918, no truly independent Polish state existed, although strong resistance movements operated. The opportunity to regain sovereignty only materialized after World War I, when the three partitioning powers were fatally weakened in the wake of war and revolution. The Second Polish Republic was established in 1918 and existed as an independent state until 1939, when Nazi Germany and the Soviet Union invaded Poland, marking the beginning of World War II. Millions of Polish citizens of different faiths or identities perished under Nazi occupation between 1939 and 1945 through planned genocide and extermination.
=== Preparation === Harvested chilies may be used fresh, or dried, typically on the ground in hot countries, to make a variety of products. Drying enables chilies grown in temperate regions to be used in winter. For home use, chilies can be dried by threading them with cotton and hanging them up in a warm dry place to dry.
==== Specific populations ==== Modafinil exhibits sex-specific pharmacokinetic differences. It demonstrates higher bioavailability in women compared to men. The mean Cmax is higher in women than in men, 5.2 mg/L vs. 4.2 mg/L (p < 0.05), following a single 200 mg oral dose of modafinil. This difference persists even after adjusting for body weight (0.88 ml/min/kg vs. 0.72 ml/min/kg). The clearance of modafinil is 30% higher in men than in women, and plasma concentrations after a single dose are significantly higher in women than in men. These sex-specific pharmacokinetic differences may have implications for the efficacy and safety of modafinil.
=== 17 February === The SAF took control of the Kafouri area, the last RSF stronghold in Khartoum North, and the city of Er Rahad in North Kordofan. It also retook the Ministry of Animal Resources, the Tax Tower, the Malaysian Tower, and the Medical Supply Department headquarters near central Khartoum. The Sudanese government extended the opening of the Adre border crossing with Chad until 16 May to allow humanitarian aid to reach Darfur.
Sources: en.wikipedia.org
In 2016, the World Health Organization estimated that 34 million people used opioids and 19 million used opiates. Of these, about 27 million people had opioid dependence, with the majority—but a decreasing number—using illicit heroin. In 2015, 118,000 people died from opioid use disorders, causing almost one-third of all drug-related deaths.
Aseptic processing works by placing sterilized food (typically by heat, see ultra-high temperature processing) into sterilized packaging material under sterile conditions. The result is a sealed, sterile food product similar to canned food, but depending on the technique used, damage to food quality is typically reduced compared to canned food. A greater variety of packaging materials can be used as well. Besides UHT, aseptic processing may be used in conjunction with any of the microbe-reduction technologies listed below. With pasteurization and "high pressure pasteurization", the food may not be completely sterilized (instead achieving a specified log reduction), but the use of sterile packaging and environments is retained.
Clinicians may improperly connect transgender people's symptoms to their gender transition, a phenomenon known as trans broken arm syndrome. Trans broken arm syndrome is particularly prevalent among mental health practitioners, but exists in all fields of medicine. Misguided investigation of transition-related causes can frustrate patients and cause delay in or refusal of treatment, or misdiagnosis and prescription of a wrong treatment. Misattribution of symptoms to gender-affirming hormone therapy may also cause doctors to erroneously recommend the patient stop taking hormones. Trans broken arm syndrome may also manifest as health insurance companies refusing to pay for treatments, claiming that a mental or physical health problem is inevitable or untreatable due to the patient's transgender status or that a treatment would be too experimental because the patient is transgender. According to The SAGE Encyclopedia of Trans Studies, trans broken arm syndrome is a form of discrimination against transgender people. A 2021 survey by TransActual shows that 57% of transgender people in the United Kingdom put off seeing a doctor when they were ill. In 2014, 43% of transgender counselling clients in the UK said their counsellor "wanted to explore transgender issues in therapy even when this wasn't the reason they had sought help".
Acanthodrilidae Ailoscolecidae – the Pyrenees and the Southeastern United States Almidae – tropical equatorial (South America, Africa, Indo-Asia) Benhamiinae – Ethiopian, Neotropical (a possible subfamily of Octochaetidae) Criodrilidae – southwestern Palaearctic: Europe, Middle East, Russia and Siberia to Pacific coast; Japan (Biwadrilus); mainly aquatic Diplocardiinae – Gondwanan or Laurasian? (subfamily of Acanthodrilidae) Enchytraeidae – cosmopolitan but uncommon in tropics (usually classed with Microdriles) Eudrilidae – Tropical Africa south of the Sahara Exxidae – Neotropical: Central America and the Caribbean Glossoscolecidae – Neotropical: Central and South America, Caribbean Haplotaxidae – cosmopolitan distribution (usually classed with Microdriles) Hormogastridae – Mediterranean Kynotidae – Malagasian: Madagascar Lumbricidae – Holarctic: North America, Europe, Middle East, Central Asia to Japan Lutodrilidae – Louisiana, in the Southeastern United States Megascolecidae Microchaetidae – Terrestrial in Africa especially South African grasslands Moniligastridae – Oriental and Indian subregion Ocnerodrilidae – Neotropics, Africa; India Octochaetidae – Australasian, Indian, Oriental, Ethiopian, Neotropical Octochaetidae – Australasian, Indian, Oriental (subfamily if Benhamiinae is accepted) Sparganophilidae – Nearctic, Neotropical: North and Central America Tumakidae – Colombia, South America
Laminated bars consist of different layers to reduce the weight of the bar. Solid bars are solid steel, intended for professional use. They commonly have an exchangeable nose, since the sprocket at the bar nose wears out faster than the bar. Safety bars are laminated bars with a small sprocket at the nose. The small nose reduces the kickback effect. Such bars are used on consumer saws.
Sources: en.wikipedia.org
==== World Health Organization ==== On January 22, 2026, President Donald Trump completed the withdrawal of the United States from the World Health Organization (WHO), a specialized agency of the United Nations, a year after he signed Executive Order 14155 on January 20, 2025. As announced by the Department of Health and Human Services, the United States officially exited the organization, ending its 78-year membership and halting all U.S. funding and participation in the WHO's governance and activities. Although the organization hoped for a reconsideration the day after Trump's executive order, the administration continued with the decision. The administration justified the withdrawal by citing concerns about the WHO's handling of global health emergencies, including the COVID-19 pandemic, its resistance to reforms, and its failure to operate independently from inappropriate political influence of other WHO member states. In a joint statement by Secretary of State Marco Rubio and Secretary of Health and Human Services Robert F. Kennedy Jr., they said that the WHO "tarnished and trashed everything that America has done for it" and it "abandoned its core mission and acted repeatedly against the interests of the United States", including the failure to "hand over the American flag that hung in front of it". The United States still owes outstanding dues to the WHO from 2024 to 2025, raising questions about the legality and financial implications of the exit.
aureus or Streptococcus pneumoniae, are usually considered to be pathogenic when detected in a blood culture, while others are more likely to represent contamination with skin flora; but even common skin organisms such as coagulase-negative staphylococci can cause bloodstream infections under certain conditions. When such organisms are present, interpretation of the culture result involves taking into account the person's clinical condition and whether or not multiple cultures are positive for the same organism. False negatives may be caused by drawing blood cultures after the person has received antibiotics or collecting an insufficient amount of blood. The volume of blood drawn is considered the most important variable in ensuring that pathogens are detected: the more blood that is collected, the more pathogens are recovered. However, if the amount of blood collected far exceeds the recommended volume, bacterial growth may be inhibited by natural inhibitors present in the blood and an inadequate amount of growth medium in the bottle. Over-filling of blood culture bottles may also contribute to iatrogenic anemia. Not all pathogens are easily detected by conventional blood culture methods. Particularly fastidious organisms, such as Brucella and Mycobacterium species, may require prolonged incubation times or special culture media. Some organisms are exceedingly difficult to culture or do not grow in culture at all, so serology testing or molecular methods such as PCR are preferred if infection with these organisms is suspected.
== Therapeutics == Therapeutic use of C-peptide has been explored in small clinical trials in diabetic kidney disease. Creative Peptides, Eli Lilly, and Cebix all had drug development programs for a C-peptide product. Cebix had the only ongoing program until it completed a Phase IIb trial in December 2014 that showed no difference between C-peptide and placebo, and it terminated its program and went out of business.
== History == ITGA1 was first identified in 1986 as a Very Late Antigen-1 (VLA-1), a surface protein expressed on activated T lymphocytes. Later studies demonstrated that VLA-1 corresponds to the α1 integrin subunit, which pairs with the β1 integrin subunit to fom the α1β1 heterodimer, a receptor for collagen and laminin. During the early 1990s, cloning of the human ITGA1 gene enabled detailed characterization of its structure and tissue distribution. Structural studies later identified the α1 subunit as one of the integrins containing an inserted von Willebrand factor A domain responsible for collagen recognition. More recent research has expanded the biological significance of ITGA1 beyond cell adhesion to include roles in mechanotransduction, immune regulation, fibrosis, and cancer, leading to growing interest in ITGA1 as a potential therapeutic target.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.